Overview

Tech Summary

Promoter Holding

Posts

SUNPHARMA

10123456789,201234567890012345678920123456789.2012345678900123456789
+10.85 (+0.91%)
The current prices are delayed.Login/Sign Upto see live prices.
Previous Close: 1191.35
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
1184.5
Today's high
1209.5
52 week low
856.8
52 week high
1214.8
Volume
1813462
About
TECHNICAL SUMMARY
DMA(12)
₹1028.68
DMA(50)
₹988.87
DMA(100)
₹939.14
DMA(200)
₹907.73
FUNDEMANTAL SUMMARY
Market Cap
₹288443.85 Cr.
Enterprise Value
₹288871.44 Cr.
No. of Shares
239.93
P/E
34.2
RoE
16.46
Debt/Equity
0.11
Valuations
PE CHART
140160180200220240260
PB CHART
4.04.24.44.64.8
Promoter Holdings
Public : 9.29%
FII : 16.48%
DII : 19.75%
Promoter : 54.48%
Others : 0%
Charts
DEBT/EQUITY
0.050.100.150.200.25
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE VS ROCE
681012141618
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE
ROCE
REVENUE VS PROFITABILITY (1000CR.)
10203040
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Revenue
Profit
MARGINS(%)
1015202530
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Net Margin
Gross Margin
Posts by FrontPage Users
Bhav Bhagwan-display-image
Reputation: 8,915  •  Yesterday 2:16 PM

#SHORT_TERM  
Stock : SUN PHARMA
CMP Above : 280
Stop loss : 255
Target : 300 : 320: 350
  
Disclaimer : This is strictly for educational purposes only not a buying recommendation
Positional Bets - chart - 228653960

11 Votes

5 Comments
Share
Add a comment
Manush Vadher-display-image
Reputation: 23,577  •  Nov 27 4:04 PM

#SunPharma Daily
Rising Channel formation
Stock already faced resistance 1200-1220 zone
Divergence also there...
PS ~ Already double top formation
Chartbusters - chart - 228634030

Vote

Comment
Share
Add a comment
I
Reputation: 2,436  •  Nov 24 10:27 PM

Vote

Comment
Share
Add a comment
D
Reputation: 96  •  Nov 24 6:59 AM

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 23 5:31 PM
Param Desai’s 4 top picks in largecap and midcap pharma
Param Desai’s 4 top picks in largecap and midcap pharma
“We believe that Ciplas Pithampur facility was inspected in February and post that, they got an OAI in August and post that, it has escalated to a warning letter. We believe that it is unlikely that this will escalate further to import alerts, though this may take some time to resolve.”
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Cipla's Pithampur facility received an OAI in August and a warning letter in February, but it is unlikely to escalate to import alerts.
• Top picks in largecaps are Sun Pharma and Cipla, while in midcaps, Torrent Pharma and JB Chemicals are preferred.
• ......read more

Vote

Comment
Share
Add a comment
F
Reputation: 40,347  •  Nov 15 1:22 PM


TIME FRAME:--- 15MIN
BULLISH FLAG PATTERN
Chartbusters - chart - 219243301

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 13 7:56 PM
Bullish setups hint at further upside for Nifty: Analysts
Bullish setups hint at further upside for Nifty: Analysts
​​Stocks such as Axis Bank, SBI, Tata Motors, Sun Pharma, Canara Bank, PFC, DLF, Godrej Properties, PI Industries, Aurobindo Pharma, and Dr Lal Path Labs have exhibited bullish trend on the charts, as per the analysts.
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Stocks such as Axis Bank, SBI, Tata Motors, Sun Pharma, Canara Bank, PFC, DLF, Godrej Properties, PI Industries, Aurobindo Pharma, and Dr Lal Path Labs have exhibited a bullish trend on the charts, according to analysts.
• Technical charts indicate that ......read more

Vote

Comment
Share
Add a comment
P
Reputation: 2,216  •  Nov 13 5:28 PM

#SUNPHARMA Looks Sell side if its break 1178-80 then we can see downside we can take option trade in this stock.

Buying SUNPHARMA 1180 PE Near 14-15, SL 11, Target 19,23,26
time Frame -3-5 Days

3 Votes

1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 9 3:01 PM
Festive cheer eludes D-Street! Sensex, Nifty dip despite firm Asian market cues
Festive cheer eludes D-Street! Sensex, Nifty dip despite firm Asian market cues
Among the Sensex stocks, Sun Pharma, Tech Mahindra, Bharti Airtel, HDFC Bank, and Reliance Industries opened with cuts, while M&M, L&T, Titan, and Tata Steel opened with gains.
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Indian equity indices opened marginally lower on Thursday amid mixed global cues, dragged by index heavyweights HDFC Bank, Reliance Industries, and Infosys.
• The BSE Sensex was trading 74 points or 0.11% lower at 64,901, while the Nifty50 was trading at......read more

3 Votes

Comment
Share
Add a comment
Stock Craze-display-image
Reputation: 6,260  •  Nov 8 6:21 AM

- Breakout on Daily TF.🤙
- keep it on radar 😉
Chartbusters - chart - 214341936

2 Votes

Comment
Share
Add a comment
Option Scalptrades-display-image
Reputation: 20,559  •  Nov 8 12:35 AM


Breakout stock...

Looking good for an up move...

FOR EDUCATIONAL PURPOSE ONLY
Chartbusters - chart - 214319844

4 Votes

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 7 4:21 PM
Sanjiv Bhasin on why pharma is better than IT to play a weak rupee & his dark horse pick
Sanjiv Bhasin on why pharma is better than IT to play a weak rupee & his dark horse pick
“Pharma sector can be a very good proxy to a weak rupee. Rather than IT, be in pharma to play a weak rupee. That has been a splendid outperforming sector. Cipla, Sun Pharma, Aurobindo are just coming of age and I still continue to think Lupin can be a huge outperformer.”
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Pharma sector is a good proxy for a weak rupee and has been outperforming.
• Lupin is expected to deliver strong numbers and can be a dark horse play.
• Real estate stocks are expected to continue performing well in the near future.
https://economictimes......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 6 3:53 PM
Buy Sun Pharmaceutical Industries; target of Rs 1280: Prabhudas Lilladher
Buy Sun Pharmaceutical Industries; target of Rs 1280: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1280 in its research report dated November 02, 2023.
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Prabhudas Lilladher has recommended a buy rating on Sun Pharmaceutical Industries with a target price of Rs 1280.
• Sun Pharma's Q2FY24 EBIDTA was in line with estimates, aided by domestic formulation and specialty sales.
• The company's growth is more f......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 4 1:11 AM
Zydus, Lupin enter licensing pact to market drug to treat liver disease
Zydus, Lupin enter licensing pact to market drug to treat liver disease
Zydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones. With a once-daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden, and offers greater convenience for patients.
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Lifesciences and Lupin have signed a licensing and supply agreement to market Zydus' novel drug Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steato Hepatitis in India.
• Under the agreement, Lupin will ha......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 3 6:16 AM
Zydus bets big on proprietary drugs to boost revenue
Zydus bets big on proprietary drugs to boost revenue
Sharvil Patel, managing director of Zydus Lifesciences said, half of the research and development (R&D) allocation is geared towards developing new chemical entities (NCEs), biologics and differentiated products. On average, Zydus spends about 8% of its revenue on R&D, which is higher than the industry average of 6%.
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Lifesciences is focusing on proprietary and differentiated products, with the aim of generating half of its revenue from these products by 2028.
• The company is also investing heavily in research and development, with 8% of its revenue allocated t......read more

Vote

1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 2 5:09 PM

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sun Pharma's net sales in September 2023 increased by 11.32% compared to the same period in 2022.
• The company's quarterly net profit also saw a 5.01% increase in September 2023.
• Sun Pharma's EPS has increased from Rs. 9.40 to Rs. 9.90 in September 20......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 2 3:54 PM

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sun Pharma's net sales in September 2023 decreased by 3.58% compared to the same period in 2022.
• The company's net profit also decreased by 26.74% in September 2023.
• Sun Pharma's EPS has decreased from Rs. 5.10 to Rs. 3.70 in September 2023.
https://......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 2 3:11 PM
Buy Sun Pharmaceutical Industries, target price Rs 1310:  Motilal Oswal
Buy Sun Pharmaceutical Industries, target price Rs 1310: Motilal Oswal
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 268329.63 Crore) operating in Pharmaceuticals sector.
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sun Pharmaceutical Industries Ltd. is a Large Cap company operating in the Pharmaceuticals sector.
• Motilal Oswal has a buy call on the company with a target price of Rs 1310.
• For the quarter ended 30-09-2023, the company reported a Consolidated Total......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 2 2:48 PM
Sun Pharma's healthy Q2, stellar specialty sales impresses brokerages, triggers hikes in target prices
Sun Pharma's healthy Q2, stellar specialty sales impresses brokerages, triggers hikes in target prices
The healthy earnings growth for Sun Pharma was aided by strong global specialty sales and an industry-beating performance in the domestic market even as US sales faltered sequentially.
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sun Pharma's Q2 results have impressed brokerages, with some raising their target prices for the stock.
• The drugmaker reported a 5% increase in net profit and an 11.3% increase in revenue, beating Street estimates.
• The growth was driven by strong glo......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,006  •  Nov 2 1:31 AM
Sun Pharma Q2 Results: Net profit rises 5% YoY to Rs 2,376 crore
Sun Pharma Q2 Results: Net profit rises 5% YoY to Rs 2,376 crore
The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 7.5% to Rs. 3179.4 crore in Q2, and EBITDA margins declined 90 basis points YoY to 26.1%. India formulation sales rose 11.1% YoY to Rs. 3843 crore in Q2FY24. India accounts for 32% of Sun Pharma sales
The Economic Times

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sun Pharma reported a 5% YoY jump in net profit to Rs 2376 crore in Q2FY24, with broad-based sales growth across markets.
• The company's India formulation sales rose 11.1% YoY to Rs. 3843 crore, accounting for 32% of Sun Pharma's sales.
• Sun Pharma's R......read more

Vote

Comment
Share
Add a comment
Load More Posts
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Stock Sentiments
87% Bullish
13% Bearish
507 live trades of Rs. 40,505,241.11
V
vijaykumaragarwal-BkSdCz58i
 
Reputation: 0 • 
59 minutes ago
SUNPHARMA DEC23 FUT
700 Qty (S) Trade entered
V
vvk-HkpuG99cs
 
Reputation: 0 • 
59 minutes ago
SUNPHARMA NOV23 1200 CE
700 Qty (S) Trade entered